Banco Santander S.A. Acquires 127 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Banco Santander S.A. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,698 shares of the biopharmaceutical company’s stock after purchasing an additional 127 shares during the quarter. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $8,092,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the stock. Pacer Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 18.7% during the third quarter. Pacer Advisors Inc. now owns 19,540 shares of the biopharmaceutical company’s stock valued at $20,541,000 after acquiring an additional 3,076 shares in the last quarter. Integrated Investment Consultants LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 85.1% during the 3rd quarter. Integrated Investment Consultants LLC now owns 570 shares of the biopharmaceutical company’s stock valued at $599,000 after purchasing an additional 262 shares during the last quarter. Cornerstone Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 13.2% during the third quarter. Cornerstone Advisors LLC now owns 6,000 shares of the biopharmaceutical company’s stock valued at $6,307,000 after purchasing an additional 700 shares in the last quarter. Moran Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 13.1% in the third quarter. Moran Wealth Management LLC now owns 22,216 shares of the biopharmaceutical company’s stock worth $23,354,000 after purchasing an additional 2,572 shares during the last quarter. Finally, Retireful LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth about $751,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.3 %

Shares of Regeneron Pharmaceuticals stock opened at $745.48 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The stock has a market cap of $81.92 billion, a price-to-earnings ratio of 18.45, a PEG ratio of 2.81 and a beta of 0.15. The firm’s 50-day moving average is $953.38 and its two-hundred day moving average is $1,028.16. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.48% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on REGN shares. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. Barclays decreased their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. StockNews.com cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, BMO Capital Markets dropped their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.